Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen Signs Third Genotyping Deal With Glaxo

NEW YORK, Sept. 1 (GenomeWeb News) - Perlegen Sciences will conduct further genetic analysis studies for GlaxoSmithKline under a new agreement, Perlegen said today.

 

The companies did not disclose any details of the agreement, other than saying that it "enables multiple genetics related studies to be conducted over a period of time."

 

Perlegen has conducted two whole-genome association studies for GSK in the past. The first, announced in September 2002, aimed at identifying drug response markers. The second, from October 2004, sought to determine genetic variants associated with a "specific GSK trait of interest."

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.